Genome-wide association study of early-stage non-small cell lung cancer prognosis: a pooled analysis in the International Lung Cancer Consortium

Authors:

Abstract
Lung cancer is the leading cause of cancer mortality. To investigate genetic determinants for prognosis among patients diagnosed with early-stage non-small cell lung cancer (NSCLC), we conducted the first large-scale genome-wide association prognostic study using data from the International Lung Cancer Consortium (ILCCO) through a two-phase analysis. Phase 1 includes the discovery of genome-wide association studies analysis using a multivariable Cox PH model on 3428 NSCLC patients of European ancestry from 10 ILCCO participating studies to identify genetic variants associated with overall survival and validation analysis for genome-wide significant variants (P-value ≤5 × 10−8) using the Cancer Genome Atlas (TCGA). Phase 2 aims to identify causal variants using functional analyses of genome-wide significant and suggestive variants (P-value ≤1 × 10−5), including variant-epigenetic functional annotation (FAVOR), CHIP-seq data, variant-gene expression association, and colocalization analysis. We identified two significant variants; of those, a locus at 9q21.31 (rs117979484) was significant at the genome-wide level (P = 3.67 × 10−8) and validated in TCGA (P = 0.03). Three suggestive variants were found to have a putative epigenetic function: intronic variants rs149281784 (BCL7B gene) and rs148031766 (POM121 gene) both located at 7q11.23 and in moderate linkage disequilibrium with each other; and variant rs2471630 (SRCIN1 gene; 17q12). Specifically, variants rs149281784 and rs148031766 have potential regulatory roles in the transcriptional activation of the BCL7B gene and POM121 gene. Exploratory survival analyses in the squamous cell carcinomas subgroup also identified a significant variant, rs138467404 (GRHL-2 gene; 8q22.3) at a genome-wide level (P = 4.75 × 10−8) and validated by TCGA (P = 0.02). These new findings indicate potential novel pathways associated with early-stage NSCLC prognosis. Future research may validate additional genome-wide suggestive variants as being relevant for lung cancer outcomes.
Funding Information
  • Alan B. Brown Chair
  • The Posluns Family Fund
  • The Lusi Wong Fund
  • Princess Margaret Cancer Foundation
  • CARET Beta Carotene and Retinol Efficacy Trial
  • National Cancer Institute
  • National Institutes of Health (U01-CA063673)
  • National Institutes of Health (UM1-CA167462)
  • National Institutes of Health (U01-CA167462)
  • National Institutes of Health (U19 CA203654)
  • Fred Hutchinson Cancer Center (U01-CA209414)
  • Fred Hutchinson Cancer Center (P30000002)
  • Roy Castle Lung Cancer Foundation
  • Moffitt's Cancer Center (P30-CA076292)
  • Sheffield Hospitals Charity
  • Weston Park Hospital Cancer Charity
  • Intramural Research Program, Division of Cancer Epidemiology and Genetics

This publication has 49 references indexed in Scilit: